

Supplementary Information

Contents


1. General Information	2
2. Reaction optimization	3
3. General Procedures for the Synthesis of 3	5
4. Characterization of Compounds.	6
5. Crystallographic data collection for compound 3ba	22
6. HPLC chromatograms of compounds.	24
7. NMR Spectra of compounds.	61
8. References.....	103

1. General Information.

All reactions were carried out in oven-dried glassware with magnetic stirring. Reagents were obtained from commercial supplier and used without further purification unless otherwise noted. Solvents were dried with standard methods and freshly distilled prior to use if needed. All reactions sensitive to air or moisture were carried out under nitrogen using standard Schlenk and vacuum line techniques. NMR spectra were recorded on a 400 MHz NMR spectrometer with CDCl₃ as the solvent and TMS as an internal standard (400 MHz for ¹H and 100 MHz for ¹³C). HRMS were determined on a Q-TOF Micro LC/MS System ESI spectrometer. Enantiomeric excesses values were determined with HPLC (chiral column; mobile phase hexane/i-PrOH). Phenyl allyl ketone **1**^[1] and β,γ -unsaturated α -ketoamide **2**^[2] were either employed directly from commercial sources or prepared according to the literature.

2. Reaction optimization


1) Effect of Ligands^a



Entry	Ligand	Time (h)	Yield (%) ^b	Dr ^c	Ee (%) ^d
1	\mathbf{L}_1 (Ar = Ph, n = 2)	24	80	>20:1	85
2	\mathbf{L}_2 (Ar = 4-CH ₃ C ₆ H ₄ , n = 2)	24	82	>20:1	85
3	\mathbf{L}_3 (Ar = 4-ClC ₆ H ₄ , n = 2)	24	81	>20:1	85
4	\mathbf{L}_4 (Ar = 4-CF ₃ C ₆ H ₄ , n = 2)	24	92	>20:1	95
5	\mathbf{L}_5 (Ar = 2-thienyl, n = 2)	24	85	>20:1	70
6	\mathbf{L}_6 (Ar = 2-naphthyl, n = 2)	24	70	>20:1	82
7	\mathbf{L}_7 (Ar = Ph, n = 1)	24	84	>20:1	30
8	\mathbf{L}_8 (Ar = 4-CH ₃ C ₆ H ₄ , n = 1)	24	81	>20:1	27
9	\mathbf{L}_9 (Ar = 4-CF ₃ C ₆ H ₄ , n = 1)	24	83	>20:1	33

^aReaction conditions: **1a** (0.1 mmol), **2a** (0.1 mmol), ligand (10 mol%), ZnEt₂ (20 mol%) in THF (1 mL) under N₂ at 25 °C for 24 h. ^bIsolated yields. ^cDetermined by ¹H NMR. ^dDetermined by chiral HPLC analysis.


2) Effect of the loading of Ligands^a



Entry	X	Time (h)	Yield (%) ^b	Dr ^c	Ee (%) ^d
1	1	72	78	>20:1	94
2	2	48	80	>20:1	94
3	5	48	80	>20:1	95
4	10	24	92	>20:1	95
5	15	24	91	>20:1	94
6	20	24	92	>20:1	95

^aReaction conditions: **1a** (0.1 mmol), **2a** (0.1 mmol), ligand **L₄** (X mol%), ZnEt₂ (2X mol%) in THF (1 mL) under N₂ at 25 °C for 24 h. ^bIsolated yields. ^cDetermined by ¹H NMR. ^dDetermined by chiral HPLC analysis.


3) Effect of Solvents^a



Entry	Solvent	Time (h)	Yield (%) ^b	Dr ^c	Ee (%) ^d
1	CH ₂ Cl ₂	24	82	>20:1	94
2	CHCl ₃	48	68	>20:1	84
3	CH ₃ CN	48	72	>20:1	72
4	THF	24	92	>20:1	95
5	Toluene	30	85	>20:1	83
6	1,4-dioxane	48	77	>20:1	85

^aReaction conditions: **1a** (0.1 mmol), **2a** (0.1 mmol), ligand **L₄** (10 mol%), ZnEt₂ (20 mol%) in a specified solvent (1 mL) under N₂ at 25 °C for 24 h. ^bIsolated yields. ^cDetermined by ¹H NMR. ^dDetermined by chiral HPLC analysis.


4) Effect of more Temperatures^a



Entry	T (°C)	Time (h)	Yield (%) ^b	Dr ^c	Ee (%) ^d
1	-10	96	69	>20:1	85
2	0	72	80	>20:1	90
3	10	48	78	>20:1	90
5	20	24	86	>20:1	92
6	25	24	92	>20:1	95
7	30	24	92	>20:1	94

^aReaction conditions: **1a** (0.1 mmol), **2a** (0.1 mmol), ligand **L₄** (10 mol%), ZnEt₂ (20 mol%) in THF (1 mL) under N₂ for 24 h. ^bIsolated yields. ^cDetermined by ¹H NMR. ^dDetermined by chiral HPLC analysis.


5) Effect of Additives^a



Entry	Additive (20 mol%)	Time (h)	Yield (%) ^b	Dr ^c	Ee (%) ^d
1	None	24	92	>20:1	95
2	4A MS	24	85	>20:1	88
3	DABCO	24	80	>20:1	43
4	K ₂ CO ₃	24	83	>20:1	30
5	PPh ₃	24	86	>20:1	95
6	PPh ₃ S	24	84	>20:1	95
7	Et ₃ N	24	78	>20:1	46


^aReaction conditions: **1a** (0.1 mmol), **2a** (0.1 mmol), ligand **L₄** (10 mol%), ZnEt₂ (20 mol%) in THF (1 mL) under N₂ at 25 °C for 24 h. ^bIsolated yields. ^cDetermined by ¹H NMR. ^dDetermined by chiral HPLC analysis.

3. General Procedures for the Synthesis of 3.



In a flame-dried Schlenk tube, a solution of diethylzinc (0.04 mL, 1.0 mol L⁻¹ in hexane, 0.02 mmol) was added to a solution of the chiral ligand **L4** (9.1 mg, 0.01 mmol) in dry THF (1.0 mL) under nitrogen at 25 °C. The mixture was stirred at 25 °C for 30 min. Then, phenyl allyl ketone **1** and β,γ -unsaturated α -ketoamide **2** was added under an argon atmosphere. The solution was stirred at 25 °C for the necessary reaction time, and then quenched with aqueous NH₄Cl (5 mL), and extracted three times with EA (3×10 mL). The combined organics was washed with brine before being dried by MgSO₄, filtered and concentrated in vacuo. The crude product was separated by flash column chromatography on silica gel (petroleum ether/ethyl acetate 5:1).


Failed examples:



Possible reasons: aliphatic variant **1q** is more active than aryl one. Under standard conditions, the reaction was messy and **1q** decomposed. On the other hand, without the aryl group, **1s** is less active to generate the dienolate, so we got the no reaction result.


4. Characterization of Compounds.

(*2S,3S,4R*)-*N*-methyl-2-(2-oxo-2-phenylethyl)-*N*,3,4-triphenyl-3,4-dihydro-2*H*-pyran-6-carboxamide **3aa**:




White solid, M.p.: 173-174 °C; yield: 92%; $[\alpha]^{25}_D = +92$ (*c* 0.1, CH₂Cl₂); HPLC (Chiralpak IF, *i*-propanol/hexane = 30/70, flow rate 1.0 mL/min, λ = 254 nm), t_1 = 13.29 min (minor), t_2 = 15.52 min (major), *ee* = 95%; ¹H NMR (400 MHz, CDCl₃) δ ppm: 7.70-7.54 (m, 2H), 7.46-7.42 (m, 1H), 7.33-7.30 (m, 2H), 7.17-7.13 (m, 3H), 7.07-6.99 (m, 8H), 6.76-6.75 (m, 2H), 6.62-6.60 (m, 2H), 5.48 (d, *J* = 2.0 Hz, 1H), 4.61-4.56 (m, 1H), 3.53-3.50 (m, 1H), 3.23 (s, 3H), 2.60-2.54 (m, 1H), 2.49-2.42 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ ppm: 196.5, 165.1, 148.2, 144.9, 142.1, 139.6, 137.1, 133.0, 129.1, 128.6, 128.3, 128.1, 127.8, 127.1, 126.7, 126.6, 126.0, 110.3, 75.8, 52.0, 46.7, 41.4, 38.0; HRMS (ESI) Calcd. For C₃₃H₂₉NO₃Na⁺ [M+Na]⁺ 510.2040, found 510.2047.

(*2S,3S,4R*)-4-(4-fluorophenyl)-*N*-methyl-2-(2-oxo-2-phenylethyl)-*N*,3-diphenyl-3,4-dihydro-2*H*-pyran-6-carboxamide **3ba**:




White solid, M.p.: 162-163 °C; yield: 88%; $[\alpha]^{25}_D = +76$ (*c* 0.1, CH₂Cl₂); HPLC (Chiralpak IA, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm), t_1 = 12.44 min (major), t_2 = 25.92 min (minor), *ee* = 93%; ¹H NMR (400 MHz, CDCl₃) δ ppm: 7.75-7.70 (m, 2H), 7.60-7.52 (m, 1H), 7.44-7.40 (m, 2H), 7.29-7.23 (m, 3H), 7.18-7.12 (m, 5H), 6.86-6.74 (m, 4H), 6.68-6.59 (m, 2H), 5.53 (d, *J* = 2.2 Hz, 1H), 4.70-4.60 (m, 1H), 3.62-3.59 (m, 1H), 3.34 (s, 3H), 2.71-2.65 (m, 1H), 2.59-2.51 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ ppm: 196.4, 165.0, 161.5 (*J* = 243.3 Hz), 148.4, 144.8, 139.3, 137.8, 137.8, 137.0, 133.0, 129.2 (*J* = 7.8 Hz), 128.7, 128.4, 128.3, 128.1, 127.3, 126.7, 125.9, 114.9 (*J* = 21.1 Hz), 110.0, 75.9, 52.1, 46.0, 41.3, 38.0; HRMS (ESI) Calcd. For C₃₃H₂₈FNO₃Na⁺ [M+Na]⁺ 528.1945, found 528.1953.

(*2S,3S,4R*)-4-(4-chlorophenyl)-*N*-methyl-2-(2-oxo-2-phenylethyl)-*N*,3-diphenyl-3,4-dihydro-2*H*-pyran-6-carboxamide **3ca**:




White solid, M.p.: 135-136 °C; yield: 82%; $[\alpha]^{25}_D = +83$ (*c* 0.1, CH₂Cl₂); HPLC (Chiralpak IA, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm), t_1 = 13.24 min (major), t_2 = 27.69 min (minor), *ee* = 92%; ¹H NMR (400 MHz, CDCl₃) δ ppm: 7.61-7.59 (m, 2H), 7.45-7.42 (m, 1H), 7.33-7.29 (m, 2H), 7.19-7.13 (m, 3H), 7.07-7.01 (m, 5H), 6.95-6.93 (m, 2H), 6.75-6.74 (m, 2H), 6.50 (d, J = 8.4 Hz, 2H), 5.39 (d, J = 2.1 Hz, 1H), 4.59-4.54 (m, 1H), 3.51-3.48 (m, 1H), 3.23 (s, 3H), 2.61-2.55 (m, 1H), 2.49-2.40 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ ppm: 196.4, 165.0, 148.6, 144.8, 140.7, 139.2, 137.0, 133.0, 132.3, 129.1, 129.1, 128.7, 128.4, 128.3, 128.1, 127.3, 126.8, 125.9, 109.6, 75.9, 51.9, 46.1, 41.3, 38.0; HRMS (ESI) Calcd. For C₃₃H₂₈ClNO₃Na⁺ [M+Na]⁺ 544.1650, found 544.1656.

(2*S*,3*S*,4*R*)-4-(4-bromophenyl)-*N*-methyl-2-(2-oxo-2-phenylethyl)-*N*,3-diphenyl-3,4-dihydro-2*H*-pyran-6-carboxamide **3da**:



White solid, M.p.: 153-154 °C; yield: 83%; $[\alpha]^{25}_D = +105$ (*c* 0.1, CH₂Cl₂); HPLC (Chiralpak IA, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm), t_1 = 14.00 min (major), t_2 = 29.54 min (minor), *ee* = 93%; ¹H NMR (400 MHz, CDCl₃) δ ppm: 7.73-7.71 (m, 2H), 7.56-7.52 (m, 1H), 7.45-7.41 (m, 2H), 7.31-7.29 (m, 2H), 7.17-7.09 (m, 6H), 7.01-6.99 (m, 2H), 6.88-6.86 (m, 2H), 6.73-6.70 (m, 2H), 5.64 (d, J = 2.2 Hz, 1H), 4.75-4.69 (m, 1H), 3.65-3.62 (m, 1H), 3.28 (s, 3H), 2.72-2.66 (m, 1H), 2.61-2.49 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ ppm: 196.4, 164.8, 147.8, 144.0, 141.9, 139.5, 136.9, 133.1, 132.2, 128.7, 128.5, 128.3, 128.2, 128.1, 127.8, 127.4, 127.2, 126.7, 120.2, 111.1, 75.8, 51.8, 46.8, 41.2, 38.0; HRMS (ESI) Calcd. For C₃₃H₂₈BrNO₃Na⁺ [M+Na]⁺ 588.1145, found 588.1151.


(2*S*,3*S*,4*R*)-*N*-methyl-2-(2-oxo-2-phenylethyl)-*N*,3-diphenyl-4-(*p*-tolyl)-3,4-dihydro-2*H*-pyran-6-carboxamide **3ea**:



White solid, M.p.: 122-123 °C; yield: 82%; $[\alpha]^{25}_D = +57$ (*c* 0.1, CH₂Cl₂); HPLC (Chiralpak IA, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm), t_1 = 12.14 min (major), t_2 = 21.64 min (minor), *ee* = 94%; ¹H NMR (400 MHz, CDCl₃) δ ppm: 7.62-7.60 (m, 2H), 7.46-7.42 (m, 1H), 7.34-7.30 (m, 2H), 7.18-7.13 (m, 3H), 7.07-7.01 (m, 5H), 6.81-6.76 (m, 4H), 6.50 (d, J = 8.0 Hz, 2H), 5.46 (d, J = 2.2 Hz, 1H), 4.59-4.54 (m, 1H), 3.51-3.47 (m, 1H), 3.23 (s, 3H), 2.60-2.54 (m, 1H), 2.48-2.42 (m, 2H), 2.14 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ ppm: 196.6, 165.2, 148.1, 144.9, 139.7, 139.0, 137.1, 136.0, 133.0, 129.1, 128.8, 128.6, 128.4, 128.3, 128.1, 127.6, 127.1, 126.7, 126.0,


110.6, 75.9, 51.9, 46.2, 41.4, 37.9, 21.0; HRMS (ESI) Calcd. For $C_{34}H_{31}NO_3Na^+$ $[M+Na]^+$ 524.2196, found 524.2207.

(*2S,3S,4R*)-4-(3-bromophenyl)-*N*-methyl-2-(2-oxo-2-phenylethyl)-*N*,3-diphenyl-3,4-dihydro-2*H*-pyran-6-carboxamide **3fa**:




White solid, M.p.: 112-113 °C; yield: 89%; $[\alpha]^{25}_D = +88$ (*c* 0.1, CH_2Cl_2); HPLC (Chiralpak IA, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 14.82$ min (major), $t_2 = 30.70$ min (minor), *ee* = 93%; 1H NMR (400 MHz, $CDCl_3$) δ ppm: 7.72-7.68 (m, 2H), 7.58-7.51 (m, 1H), 7.44-7.38 (m, 2H), 7.31-7.23 (m, 4H), 7.19-7.09 (m, 5H), 6.96-6.92 (m, 2H), 6.86-6.85 (m, 2H), 6.59 (d, $J = 7.7$ Hz, 1H), 5.52 (d, $J = 2.2$ Hz, 1H), 4.70-4.65 (m, 1H), 3.60-3.57 (m, 1H), 3.33 (s, 3H), 2.71-2.64 (m, 1H), 2.58-2.51 (m, 2H); ^{13}C NMR (100 MHz, $CDCl_3$) δ ppm: 196.4, 164.9, 148.7, 144.7, 144.5, 139.0, 137.0, 133.0, 130.6, 129.8, 129.6, 129.1, 128.8, 128.4, 128.3, 128.1, 127.4, 127.0, 126.7, 126.0, 122.2, 109.2, 75.8, 51.7, 46.5, 41.3, 37.9; HRMS (ESI) Calcd. For $C_{33}H_{28}BrNO_3Na^+$ $[M+Na]^+$ 588.1145, found 588.1153.

(*2S,3S,4R*)-4-(3,4-dimethylphenyl)-*N*-methyl-2-(2-oxo-2-phenylethyl)-*N*,3-diphenyl-3,4-dihydro-2*H*-pyran-6-carboxamide **3ga**:



White solid, M.p.: 127-128 °C; yield: 90%; $[\alpha]^{25}_D = +121$ (*c* 0.1, CH_2Cl_2); HPLC (Chiralpak IA, *i*-propanol/hexane = 40/60, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 11.32$ min (major), $t_2 = 13.18$ min (minor), *ee* = 90%; 1H NMR (400 MHz, $CDCl_3$) δ ppm: 7.62-7.60 (m, 2H), 7.46-7.42 (m, 1H), 7.34-7.30 (m, 2H), 7.18-7.10 (m, 3H), 7.07-6.99 (m, 5H), 6.79-6.73 (m, 3H), 6.49-6.45 (m, 1H), 6.34-6.32 (m, 1H), 5.47 (d, $J = 2.2$ Hz, 1H), 4.58-4.52 (m, 1H), 3.48-3.45 (m, 1H), 3.23 (s, 3H), 2.61-2.54 (m, 1H), 2.50-2.41 (m, 2H), 2.05 (s, 3H), 2.00 (s, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ ppm: 196.6, 165.2, 148.0, 144.9, 139.8, 139.4, 137.1, 136.2, 134.6, 133.0, 129.3, 129.0, 128.9, 128.6, 128.4, 128.3, 128.1, 127.0, 126.7, 126.0, 125.2, 110.8, 75.9, 51.8, 46.2, 41.5, 37.9, 19.7, 19.3; HRMS (ESI) Calcd. For $C_{35}H_{33}NO_3Na^+$ $[M+Na]^+$ 538.2353, found 538.2355.


(*2S,3S,4R*)-*N*-methyl-4-(naphthalen-2-yl)-2-(2-oxo-2-phenylethyl)-*N*,3-diphenyl-3,4-dihydro-2*H*-pyran-6-carboxamide **3ha**:



3ha

White solid, M.p.: 137-138 °C; yield: 94%; $[\alpha]^{25}_D = +90$ (*c* 0.1, CH₂Cl₂); HPLC (Chiralpak IA, *i*-propanol/hexane = 40/60, flow rate 1.0 mL/min, λ = 254 nm), t_1 = 8.81 min (major), t_2 = 16.56 min (minor), *ee* = 92%; ¹H NMR (400 MHz, CDCl₃) δ ppm: 7.65-7.62 (m, 3H), 7.56-7.52 (m, 1H), 7.50-7.43 (m, 2H), 7.35-7.28 (m, 3H), 7.22-7.14 (m, 4H), 7.12-7.09 (m, 3H), 7.04-6.97 (m, 3H), 6.78-6.73 (m, 3H), 5.55 (d, *J* = 2.1 Hz, 1H), 4.66-4.61 (m, 1H), 3.71-3.68 (m, 1H), 3.26 (s, 3H), 2.65-2.58 (m, 2H), 2.50-2.45 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ ppm: 196.6, 165.2, 148.3, 144.9, 139.6, 139.5, 137.0, 133.3, 133.0, 132.4, 129.1, 128.7, 128.4, 128.1, 127.7, 127.6, 127.5, 127.2, 126.8, 126.4, 126.1, 126.0, 125.8, 125.4, 110.2, 75.9, 51.8, 46.8, 41.4, 38.0; HRMS (ESI) Calcd. For C₃₇H₃₁NO₃Na⁺ [M+Na]⁺ 560.2196, found 560.2202.


(2*S*,3*S*,4*R*)-*N*-methyl-4-(naphthalen-1-yl)-2-(2-oxo-2-phenylethyl)-*N*,3-diphenyl-3,4-dihydro-2*H*-pyran-6-carboxamide **3ia**:



3ia

White solid, M.p.: 67-68 °C; yield: 87%; $[\alpha]^{25}_D = +136$ (*c* 0.1, CH₂Cl₂); HPLC (Chiralpak IF, *i*-propanol/hexane = 40/60, flow rate 1.0 mL/min, λ = 254 nm), t_1 = 10.16 min (minor), t_2 = 12.94 min (major), *ee* = 92%; ¹H NMR (400 MHz, CDCl₃) δ ppm: 7.65-7.61 (m, 3H), 7.55-7.43 (m, 3H), 7.35-7.29 (m, 4H), 7.22-7.16 (m, 3H), 7.12-7.09 (m, 3H), 7.04-6.99 (m, 3H), 6.78-6.73 (m, 3H), 5.55 (d, *J* = 2.1 Hz, 1H), 4.66-4.60 (m, 1H), 3.71-3.68 (m, 1H), 3.26 (s, 3H), 2.65-2.58 (m, 2H), 2.50-2.45 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ ppm: 196.5, 165.1, 148.4, 144.9, 139.6, 139.5, 137.1, 133.3, 133.0, 132.4, 129.1, 128.7, 128.4, 128.1, 127.7, 127.6, 127.5, 127.2, 126.8, 126.4, 126.1, 126.0, 125.8, 125.4, 110.2, 75.9, 51.8, 46.8, 41.4, 38.0; HRMS (ESI) Calcd. For C₃₇H₃₁NO₃Na⁺ [M+Na]⁺ 560.2196, found 560.2199.

(2*S*,3*S*,4*R*)-*N*-methyl-2-(2-oxo-2-phenylethyl)-*N*,3-diphenyl-4-(thiophen-2-yl)-3,4-dihydro-2*H*-pyran-6-carboxamide **3ja**:




3ja

White solid, M.p.: 148-149 °C; yield: 68%; $[\alpha]^{25}_D = +48$ (*c* 0.1, CH₂Cl₂); HPLC (Chiralpak IA, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm), t_1 = 14.57


min (major), $t_2 = 30.27$ min (minor), $ee = 91\%$; ^1H NMR (400 MHz, CDCl_3) δ ppm: 7.72-7.70 (m, 2H), 7.55-7.52 (m, 1H), 7.43-7.39 (m, 2H), 7.28-7.24 (m, 3H), 7.17-7.11 (m, 4H), 7.05-7.03 (m, 2H), 6.86-6.75 (m, 2H), 6.61-6.49 (m, 2H), 5.50 (d, $J = 2.0$ Hz, 1H), 4.70-4.65 (m, 1H), 3.61-3.58 (m, 1H), 3.33 (s, 3H), 2.71-2.65 (m, 1H), 2.59-2.50 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ ppm: 196.4, 165.0, 148.5, 144.8, 140.7, 139.2, 137.0, 133.1, 132.2, 129.2, 129.1, 128.8, 128.4, 128.3, 128.2, 128.1, 127.3, 126.8, 125.9, 109.6, 75.8, 51.9, 46.1, 41.2, 38.0; HRMS (ESI) Calcd. For $\text{C}_{31}\text{H}_{27}\text{NO}_3\text{SNa}^+ [\text{M}+\text{Na}]^+$ 516.1604, found 516.1606.

(*2S,3S,4R*)-*N*-(4-fluorophenyl)-*N*-methyl-2-(2-oxo-2-phenylethyl)-3,4-diphenyl-3,4-dihydro-2*H*-pyran-6-carboxamide **3ka**:




White solid, M.p.: 148-149 °C; yield: 87%; $[\alpha]^{25}_D = +79$ (c 0.1, CH_2Cl_2); HPLC (Chiralpak IA, *i*-propanol/hexane = 40/60, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 8.92$ min (major), $t_2 = 14.27$ min (minor), $ee = 92\%$; ^1H NMR (400 MHz, CDCl_3) δ ppm: 7.62-7.60 (m, 2H), 7.46-7.43 (m, 1H), 7.34-7.30 (m, 2H), 7.19-7.13 (m, 3H), 7.07-7.02 (m, 5H), 6.75-6.74 (m, 2H), 6.69-6.65 (m, 2H), 6.56-6.52 (m, 2H), 5.42 (d, $J = 2.1$ Hz, 1H), 4.60-4.55 (m, 1H), 3.52-3.48 (m, 1H), 3.24 (s, 3H), 2.61-2.55 (m, 1H), 2.49-2.40 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ ppm: 196.4, 165.0, 161.5 ($J = 243.1$ Hz), 148.4, 144.8, 139.3, 137.8, 137.0, 133.0, 129.2 ($J = 8.0$ Hz), 129.1, 128.7, 128.4, 128.3, 127.3, 126.7, 125.9, 114.9 ($J = 21.1$ Hz), 110.0, 75.9, 52.1, 46.0, 41.3, 38.0; HRMS (ESI) Calcd. For $\text{C}_{33}\text{H}_{28}\text{FNO}_3\text{Na}^+ [\text{M}+\text{Na}]^+$ 528.1945, found 528.1957.

(*2S,3S,4R*)-*N*-(4-chlorophenyl)-*N*-methyl-2-(2-oxo-2-phenylethyl)-3,4-diphenyl-3,4-dihydro-2*H*-pyran-6-carboxamide **3la**:




White solid, M.p.: 148-149 °C; yield: 88%; $[\alpha]^{25}_D = +28$ (c 0.1, CH_2Cl_2); HPLC (Chiralpak IA, *i*-propanol/hexane = 40/60, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 8.97$ min (major), $t_2 = 14.23$ min (minor), $ee = 92\%$; ^1H NMR (400 MHz, CDCl_3) δ ppm: 7.76-7.74 (m, 2H), 7.58-7.55 (m, 1H), 7.47-7.43 (m, 2H), 7.19-7.07 (m, 10H), 6.90-6.89 (m, 2H), 6.76-6.74 (m, 2H), 5.68 (d, $J = 2.2$ Hz, 1H), 4.77-4.72 (m, 1H), 3.68-3.65 (m, 1H), 3.31 (s, 3H), 2.76-2.70 (m, 1H), 2.64-2.52 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ ppm: 196.4, 164.8, 147.9, 143.5, 141.9, 139.5, 136.9, 133.1, 132.3, 129.2, 128.7, 128.5, 128.3, 128.2, 128.1, 127.8, 127.2, 127.1, 126.7, 111.1, 75.8, 51.8, 46.8, 41.3, 38.1; HRMS (ESI) Calcd. For $\text{C}_{33}\text{H}_{28}\text{ClNO}_3\text{Na}^+ [\text{M}+\text{Na}]^+$ 544.1650, found 544.1661.

(*2S,3S,4R*)-*N*-(4-bromophenyl)-*N*-methyl-2-(2-oxo-2-phenylethyl)-3,4-diphenyl-3,4-dihydro-2*H*-pyran-6-carboxamide **3ma**:




White solid, M.p.: 161-162 °C; yield: 88%; $[\alpha]^{25}_D = +107$ (*c* 0.1, CH₂Cl₂); HPLC (Chiralpak IA, *i*-propanol/hexane = 40/60, flow rate 1.0 mL/min, λ = 254 nm), t_1 = 9.28 min (major), t_2 = 14.71 min (minor), *ee* = 92%; ¹H NMR (400 MHz, CDCl₃) δ ppm: 7.72-7.70 (m, 2H), 7.61-7.52 (m, 1H), 7.44-7.40 (m, 2H), 7.30-7.24 (m, 3H), 7.23-7.20 (m, 1H), 7.19-7.11 (m, 6H), 6.85 (d, *J* = 6.5 Hz, 2H), 6.54 (d, *J* = 8.3 Hz, 2H), 5.49 (d, *J* = 2.1 Hz, 1H), 4.70-4.65 (m, 1H), 3.60-3.57 (m, 1H), 3.34 (s, 3H), 2.72-2.66 (m, 1H), 2.60-2.50 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ ppm: 196.4, 165.0, 148.5, 144.8, 141.2, 139.1, 137.0, 133.1, 131.2, 129.5, 129.1, 128.8, 128.4, 128.3, 128.1, 127.3, 126.8, 125.9, 120.4, 109.5, 75.9, 51.8, 46.1, 41.2, 38.0; HRMS (ESI) Calcd. For C₃₃H₂₈BrNO₃Na⁺ [M+Na]⁺ 588.1145, found 588.1156.

(*2S,3S,4R*)-*N*-methyl-2-(2-oxo-2-phenylethyl)-3,4-diphenyl-*N*-(p-tolyl)-3,4-dihydro-2*H*-pyran-6-carboxamide **3na**:



White solid, M.p.: 126-127 °C; yield: 85%; $[\alpha]^{25}_D = +76$ (*c* 0.1, CH₂Cl₂); HPLC (Chiralpak IA, *i*-propanol/hexane = 30/70, flow rate 1.0 mL/min, λ = 254 nm), t_1 = 11.27 min (major), t_2 = 21.59 min (minor), *ee* = 92%; ¹H NMR (400 MHz, CDCl₃) δ ppm: 7.63-7.61 (m, 2H), 7.47-7.43 (m, 1H), 7.35-7.31 (m, 2H), 7.07-6.94 (m, 10H), 6.78-6.76 (m, 2H), 6.61-6.59 (m, 2H), 5.46 (d, *J* = 2.1 Hz, 1H), 4.63-4.59 (m, 1H), 3.54-3.51 (m, 1H), 3.21 (s, 3H), 2.62-2.56 (m, 1H), 2.51-2.45 (m, 2H), 2.23 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ ppm: 196.5, 165.1, 148.2, 142.3, 139.6, 137.1, 136.5, 133.0, 129.7, 128.6, 128.4, 128.1, 128.1, 127.8, 127.1, 126.6, 125.7, 110.2, 75.7, 52.0, 46.7, 41.5, 38.1, 21.1; HRMS (ESI) Calcd. For C₃₄H₃₁NO₃Na⁺ [M+Na]⁺ 524.2196, found 524.2208.


(*2S,3S,4R*)-*N*-(4-methoxyphenyl)-*N*-methyl-2-(2-oxo-2-phenylethyl)-3,4-diphenyl-3,4-dihydro-2*H*-pyran-6-carboxamide **3oa**:



White solid, M.p.: 161-162 °C; yield: 91%; $[\alpha]^{25}_D = +82$ (*c* 0.1, CH₂Cl₂); HPLC (Chiralpak IA, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm), t_1 = 11.92


min (major), $t_2 = 26.68$ min (minor), $ee = 90\%$; ^1H NMR (400 M, CDCl_3) δ ppm: 7.83-7.73 (m, 2H), 7.66-7.53 (m, 1H), 7.44-7.41 (m, 2H), 7.17-7.07 (m, 8H), 6.88-6.86 (m, 2H), 6.80-6.65 (m, 4H), 5.55 (s, 1H), 4.71-4.51 (m, 1H), 3.79 (s, 3H), 3.70-3.61 (m, 1H), 3.30 (s, 3H), 2.74-2.58(m, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ ppm: 196.5, 165.2, 158.2, 148.3, 142.2, 139.6, 137.8, 137.1, 132.9, 128.6, 128.4, 128.4, 128.1, 127.8, 127.1, 126.6, 114.2, 110.1, 75.8, 55.5, 52.1, 46.7, 41.6, 38.2; HRMS (ESI) Calcd. For $\text{C}_{34}\text{H}_{31}\text{NO}_4\text{Na}^+ [\text{M}+\text{Na}]^+$ 540.2145, found 540.2155.

(*2S,3S,4R*)-*N*-ethyl-2-(2-oxo-2-phenylethyl)-*N*,3,4-triphenyl-3,4-dihydro-2*H*-pyran-6-carboxamide **3pa**:




White solid, M.p.: 144-145 °C; yield: 80%; $[\alpha]^{25}_D = +26$ (c 0.1, CH_2Cl_2); HPLC (Chiralpak IF, *i*-propanol/hexane = 40/60, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 10.77$ min (minor), $t_2 = 13.72$ min (major), $ee = 60\%$; ^1H NMR (400 M, CDCl_3) δ ppm: 7.64-7.61 (m, 2H), 7.47-7.43 (m, 1H), 7.35-7.31 (m, 2H), 7.18-7.16 (m, 3H), 7.04-6.99 (m, 8H), 6.81-6.68 (m, 2H), 6.61-6.59 (m, 2H), 5.45 (d, $J = 2.1$ Hz, 1H), 4.64-4.55 (m, 1H), 3.83-3.74 (m, 1H), 3.68-3.60 (m, 1H), 3.52-3.49 (m, 1H), 2.59-2.53 (m, 1H), 2.48-2.38 (m, 2H), 1.04 (t, $J = 7.1$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ ppm: 196.6, 164.7, 148.4, 143.1, 142.2, 139.6, 137.1, 133.0, 129.0, 128.6, 128.4, 128.1, 128.1, 127.8, 127.1, 126.8, 126.6, 110.2, 75.7, 51.9, 46.7, 45.0, 41.5, 12.8; HRMS (ESI) Calcd. For $\text{C}_{34}\text{H}_{31}\text{NO}_3\text{Na}^+ [\text{M}+\text{Na}]^+$ 524.2196, found 524.2208.

(*2S,3S,4R*)-2-(2-(4-fluorophenyl)-2-oxoethyl)-*N*-methyl-*N*,3,4-triphenyl-3,4-dihydro-2*H*-pyran-6-carboxamide **3ab**:



White solid, M.p.: 133-134 °C; yield: 88%; $[\alpha]^{25}_D = +90$ (c 0.1, CH_2Cl_2); HPLC (Chiralpak IA, *i*-propanol/hexane = 30/70, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 13.75$ min (major), $t_2 = 20.33$ min (minor), $ee = 94\%$; ^1H NMR (400 M, CDCl_3) δ ppm: 7.76-7.72 (m, 2H), 7.33-7.23 (m, 3H), 7.19-7.11 (m, 5H), 7.10-7.07 (m, 5H), 6.86 (d, $J = 6.5$ Hz, 2H), 6.72-6.70 (m, 2H), 5.58 (d, $J = 2.2$ Hz, 1H), 4.70-4.64 (m, 1H), 3.64-3.61 (m, 1H), 3.34 (s, 3H), 2.69-2.61 (m, 1H), 2.58-2.51 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ ppm: 194.9, 165.7 ($J = 253.1$ Hz), 165.1, 148.2, 144.9, 142.0, 139.5, 133.5, 133.5, 130.8 ($J = 9.3$ Hz), 129.1, 128.6, 128.3, 128.1, 127.8, 127.2, 126.7, 126.6, 125.9, 115.4 ($J = 21.6$ Hz), 110.4, 75.9, 52.0, 46.7, 41.3, 37.9; HRMS (ESI) Calcd. For $\text{C}_{33}\text{H}_{28}\text{FNO}_3\text{Na}^+ [\text{M}+\text{Na}]^+$ 528.1945, found 528.1955.


(*2S,3S,4R*)-2-(2-(4-chlorophenyl)-2-oxoethyl)-*N*-methyl-*N*,3,4-triphenyl-3,4-dihydro-2*H*-pyran-6-carboxamide **3ac**:



3ac

White solid, M.p.: 136-137 °C; yield: 85%; $[\alpha]^{25}_D = +79$ (*c* 0.1, CH₂Cl₂); HPLC (Chiraldak IA, *i*-propanol/hexane = 40/60, flow rate 1.0 mL/min, λ = 254 nm), t_1 = 8.94 min (major), t_2 = 13.35 min (minor), *ee* = 90%; ¹H NMR (400 M, CDCl₃) δ ppm: 7.66-7.64 (m, 2H), 7.40-7.38 (m, 2H), 7.31-7.25 (m, 3H), 7.19-7.09 (m, 8H), 6.86-6.81 (m, 2H), 6.71-6.69 (m, 2H), 5.58 (d, *J* = 2.1 Hz, 1H), 4.69-4.63 (m, 1H), 3.64-3.60 (m, 1H), 3.34 (s, 3H), 2.68-2.60 (m, 1H), 2.58-2.51 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ ppm: 195.4, 165.1, 148.1, 144.9, 142.0, 139.4, 139.4, 135.4, 129.6, 129.1, 128.7, 128.3, 128.1, 127.8, 127.2, 126.7, 126.6, 125.9, 110.5, 75.9, 52.0, 46.7, 41.4, 38.0; HRMS (ESI) Calcd. For C₃₃H₂₈ClNO₃Na⁺ [M+Na]⁺ 544.1650, found 544.1649.


(*2S,3S,4R*)-2-(2-(4-bromophenyl)-2-oxoethyl)-*N*-methyl-*N*,3,4-triphenyl-3,4-dihydro-2*H*-pyran-6-carboxamide **3ad**:



3ad

White solid, M.p.: 171-172 °C; yield: 91%; $[\alpha]^{25}_D = +80$ (*c* 0.1, CH₂Cl₂); HPLC (Chiraldak IA, *i*-propanol/hexane = 30/70, flow rate 1.0 mL/min, λ = 254 nm), t_1 = 12.01 min (major), t_2 = 19.95 min (minor), *ee* = 95%; ¹H NMR (400 M, CDCl₃) δ ppm: 7.66-7.64 (m, 2H), 7.43-7.38 (m, 2H), 7.31-7.25 (m, 3H), 7.19-7.09 (m, 8H), 6.86-6.84 (m, 2H), 6.71-6.69 (m, 2H), 5.57 (d, *J* = 2.1 Hz, 1H), 4.68-4.63 (m, 1H), 3.63-3.60 (m, 1H), 3.34 (s, 3H), 2.68-2.60 (m, 1H), 2.58-2.51 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ ppm: 195.4, 165.1, 148.1, 144.9, 142.0, 139.4, 135.4, 129.6, 129.1, 128.7, 128.3, 128.1, 127.8, 127.2, 126.7, 126.6, 125.9, 110.5, 75.9, 52.0, 46.7, 41.4, 38.0; HRMS (ESI) Calcd. For C₃₃H₂₈BrNO₃Na⁺ [M+Na]⁺ 588.1145, found 588.1143.

(*2S,3S,4R*)-*N*-methyl-2-(2-oxo-2-(*p*-tolyl)ethyl)-*N*,3,4-triphenyl-3,4-dihydro-2*H*-pyran-6-carboxamide **3ae**:




3ae

White solid, M.p.: 122-123 °C; yield: 65%; $[\alpha]^{25}_D = +88$ (*c* 0.1, CH₂Cl₂); HPLC (Chiraldak IA, *i*-propanol/hexane = 40/60, flow rate 1.0 mL/min, λ = 254 nm), t_1 = 11.14 min (major), t_2 = 13.55 min (minor), *ee* = 94%; ¹H NMR (400 M, CDCl₃) δ ppm: 7.57-


7.46 (m, 2H), 7.20-7.14 (m, 3H), 7.12-7.08 (m, 2H), 7.07-7.02 (m, 3H), 7.00-6.96 (m, 5H), 6.75 (d, J = 6.5 Hz, 2H), 6.62-6.59 (m, 2H), 5.46 (d, J = 2.1 Hz, 1H), 4.61-4.56 (m, 1H), 3.53-3.49 (m, 1H), 3.23 (s, 3H), 2.58-2.52 (m, 1H), 2.49-2.37 (m, 2H), 2.31 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ ppm: 196.2, 165.2, 148.2, 144.9, 143.8, 142.1, 139.6, 134.6, 129.1, 129.0, 128.6, 128.3, 128.3, 128.1, 127.8, 127.1, 126.7, 126.6, 126.0, 110.3, 75.8, 51.9, 46.7, 41.2, 38.0, 21.7; HRMS (ESI) Calcd. For $\text{C}_{34}\text{H}_{31}\text{NO}_3\text{Na}^+$ $[\text{M}+\text{Na}]^+$ 524.2196, found 524.2205.

(*2S,3S,4R*)-2-(2-(4-methoxyphenyl)-2-oxoethyl)-*N*-methyl-*N*,3,4-triphenyl-3,4-dihydro-2*H*-pyran-6-carboxamide **3af**:



White solid, M.p.: 148-149 °C; yield: 76%; $[\alpha]^{25}_D$ = +98 (c 0.1, CH_2Cl_2); HPLC (Chiralpak IA, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm), t_1 = 10.85 min (major), t_2 = 33.53 min (minor), *ee* = 95%; ^1H NMR (400 M, CDCl_3) δ ppm: 7.72-7.69 (m, 2H), 7.31-7.25 (m, 3H), 7.19-7.09 (m, 8H), 6.91-6.85 (m, 4H), 6.72-6.70 (m, 2H), 5.56 (d, J = 2.2 Hz, 1H), 4.71-4.65 (m, 1H), 3.88 (s, 3H), 3.63-3.59 (m, 1H), 3.34 (s, 3H), 2.67-2.59 (m, 1H), 2.57-2.47 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ ppm: 195.0, 165.2, 163.4, 148.2, 144.9, 142.2, 139.7, 130.4, 130.2, 129.1, 128.6, 128.4, 128.1, 127.8, 127.1, 126.7, 126.5, 126.0, 113.5, 110.3, 75.9, 55.5, 52.0, 46.7, 41.0, 37.9; HRMS (ESI) Calcd. For $\text{C}_{34}\text{H}_{31}\text{NO}_4\text{Na}^+$ $[\text{M}+\text{Na}]^+$ 540.2145, found 540.2158.


(*2S,3S,4R*)-2-(2-(3-chlorophenyl)-2-oxoethyl)-*N*-methyl-*N*,3,4-triphenyl-3,4-dihydro-2*H*-pyran-6-carboxamide **3ag**:



White solid, M.p.: 171-172 °C; yield: 88%; $[\alpha]^{25}_D$ = +92 (c 0.1, CH_2Cl_2); HPLC (Chiralpak IA, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm), t_1 = 14.94 min (major), t_2 = 35.00 min (minor), *ee* = 93%; ^1H NMR (400 M, CDCl_3) δ ppm: 7.60-7.58 (m, 2H), 7.47-7.44 (m, 1H), 7.35-7.31 (m, 2H), 7.18-7.04 (m, 9H), 6.95-6.94 (m, 1H), 6.85-6.84 (m, 2H), 6.66-6.64 (m, 1H), 6.29-6.28 (m, 1H), 5.62 (d, J = 2.2 Hz, 1H), 4.60-4.54 (m, 1H), 3.90-3.87 (m, 1H), 3.23 (s, 3H), 2.51-2.43 (m, 2H), 2.38-2.33 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ ppm: 196.4, 164.9, 148.0, 145.3, 144.7, 139.5, 136.9, 133.1, 129.0, 128.8, 128.4, 128.1, 127.4, 126.7, 126.4, 126.0, 124.7, 123.6, 109.7, 75.7, 52.0, 41.8, 41.4, 37.9; HRMS (ESI) Calcd. For $\text{C}_{33}\text{H}_{28}\text{ClNO}_3\text{Na}^+$ $[\text{M}+\text{Na}]^+$ 544.1650, found 544.1654.


(*2S,3S,4R*)-2-(2-(3-methoxyphenyl)-2-oxoethyl)-*N*-methyl-*N*,3,4-triphenyl-3,4-

dihydro-2*H*-pyran-6-carboxamide **3ah**:




White solid, M.p.: 151-152 °C; yield: 80%; $[\alpha]^{25}_D = +53$ (*c* 0.1, CH₂Cl₂); HPLC (Chiralpak IA, *i*-propanol/hexane = 40/60, flow rate 1.0 mL/min, λ = 254 nm), t_1 = 7.54 min (major), t_2 = 13.42 min (minor), *ee* = 94%; ¹H NMR (400 M, CDCl₃) δ ppm: 7.24-7.14 (m, 6H), 7.09-6.97 (m, 9H), 6.76-6.74 (m, 2H), 6.61-6.59 (m, 2H), 5.47 (d, *J* = 2.2 Hz, 1H), 4.60-4.55 (m, 1H), 3.76 (s, 3H), 3.53-3.50 (m, 1H), 3.24 (s, 3H), 2.58-2.52 (m, 1H), 2.49-2.42 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ ppm: 196.3, 165.2, 159.6, 148.2, 144.9, 142.1, 139.5, 138.4, 129.3, 129.1, 128.6, 128.3, 128.1, 127.8, 127.1, 126.7, 126.6, 126.0, 120.8, 119.3, 112.5, 110.3, 75.9, 55.5, 51.9, 46.7, 41.5, 37.9; HRMS (ESI) Calcd. For C₃₃H₃₁NO₃Na⁺ [M+Na]⁺ 540.2145, found 540.2154.

(2*S*,3*S*,4*R*)-*N*-methyl-2-(2-oxo-2-(*m*-tolyl)ethyl)-*N*,3,4-triphenyl-3,4-dihydro-2*H*-pyran-6-carboxamide **3ai**:



White solid, M.p.: 162-163 °C; yield: 85%; $[\alpha]^{25}_D = +95$ (*c* 0.1, CH₂Cl₂); HPLC (Chiralpak IA, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm), t_1 = 15.05 min (major), t_2 = 33.53 min (minor), *ee* = 90%; ¹H NMR (400 M, CDCl₃) δ ppm: 7.80-7.67 (m, 2H), 7.62-7.53 (m, 1H), 7.45-7.41 (m, 2H), 7.33-7.21 (m, 3H), 7.18-7.09 (m, 5H), 7.00-6.86 (m, 4H), 6.59-6.49 (m, 2H), 5.59 (d, *J* = 2.0 Hz, 1H), 4.70-4.65 (m, 1H), 3.60-3.57 (m, 1H), 3.34 (s, 3H), 2.72-2.66 (m, 1H), 2.61-2.53 (m, 2H), 2.21 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ ppm: 196.6, 165.2, 148.1, 144.8, 142.0, 139.7, 137.6, 137.1, 129.0, 128.6, 128.4, 128.3, 128.1, 127.9, 127.3, 127.1, 126.7, 126.0, 124.9, 110.5, 75.9, 51.8, 46.6, 41.4, 38.0, 21.3; HRMS (ESI) Calcd. For C₃₄H₃₁NO₃Na⁺ [M+Na]⁺ 524.2196, found 524.2206.


(2*S*,3*S*,4*R*)-*N*-methyl-2-(2-oxo-2-(*o*-tolyl)ethyl)-*N*,3,4-triphenyl-3,4-dihydro-2*H*-pyran-6-carboxamide **3aj**:



White solid, M.p.: 104-105 °C; yield: 65%; $[\alpha]^{25}_D = +32$ (*c* 0.1, CH₂Cl₂); HPLC (Chiralpak IA, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm), t_1 = 15.43 min (major), t_2 = 27.55 min (minor), *ee* = 92%; ¹H NMR (400 M, CDCl₃) δ ppm: 7.62-


7.61 (m, 2H), 7.46-7.42 (m, 1H), 7.34-7.30 (m, 2H), 7.05-6.94 (m, 10H), 6.78-6.76 (m, 2H), 6.61-6.59 (m, 2H), 5.47 (d, $J = 2.1$ Hz, 1H), 4.62-4.58 (m, 1H), 3.54-3.51 (m, 1H), 3.21 (s, 3H), 2.62-2.45 (m, 3H), 2.22 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ ppm: 196.7, 165.3, 148.5, 142.6, 142.4, 139.8, 137.3, 136.7, 133.2, 129.9, 128.8, 128.3, 128.0, 127.3, 126.8, 125.9, 110.4, 75.9, 52.2, 46.9, 41.7, 38.3, 21.3; HRMS (ESI) Calcd. For $\text{C}_{34}\text{H}_{31}\text{NO}_3\text{Na}^+$ $[\text{M}+\text{Na}]^+$ 524.2196, found 524.2203.

(2*S*,3*S*,4*R*)-*N*-methyl-2-(2-(naphthalen-2-yl)-2-oxoethyl)-*N*,3,4-triphenyl-3,4-dihydro-2*H*-pyran-6-carboxamide **3ak**:




White solid, M.p.: 162-163 °C; yield: 93%; $[\alpha]^{25}_D = +88$ (c 0.1, CH_2Cl_2); HPLC (Chiralpak IA, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 10.70$ min (major), $t_2 = 32.63$ min (minor), *ee* = 94%; ^1H NMR (400 M, CDCl_3) δ ppm: 7.65-7.62 (m, 3H), 7.55-7.43 (m, 3H), 7.35-7.29 (m, 3H), 7.21-7.16 (m, 4H), 7.12-7.09 (m, 3H), 7.04-6.99 (m, 3H), 6.78-6.73 (m, 3H), 5.55 (d, $J = 2.1$ Hz, 1H), 4.66-4.61 (m, 1H), 3.71-3.68 (m, 1H), 3.26 (s, 3H), 2.65-2.45 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ ppm: 196.5, 165.1, 148.2, 144.7, 139.5, 139.4, 136.9, 133.1, 132.9, 132.3, 129.0, 128.6, 128.3, 128.0, 127.6, 127.5, 127.4, 127.1, 126.7, 126.3, 126.0, 125.9, 125.7, 125.3, 110.1, 75.8, 51.7, 46.7, 41.3, 37.9; HRMS (ESI) Calcd. For $\text{C}_{37}\text{H}_{31}\text{NO}_3\text{Na}^+$ $[\text{M}+\text{Na}]^+$ 560.2196, found 560.2205.

(2*S*,3*S*,4*R*)-*N*-methyl-2-(2-oxo-2-(thiophen-2-yl)ethyl)-*N*,3,4-triphenyl-3,4-dihydro-2*H*-pyran-6-carboxamide **3al**:




White solid, M.p.: 134-135 °C; yield: 58%; $[\alpha]^{25}_D = +97$ (c 0.1, CH_2Cl_2); HPLC (Chiralpak IA, *i*-propanol/hexane = 40/60, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 5.44$ min (major), $t_2 = 13.38$ min (minor), *ee* = 93%; ^1H NMR (400 M, CDCl_3) δ ppm: 7.61-7.59 (m, 2H), 7.44-7.28 (m, 3H), 7.18-7.11 (m, 3H), 7.06-6.98 (m, 4H), 6.93-6.92 (m, 2H), 6.75-6.73 (m, 2H), 6.50-6.48 (m, 2H), 5.39 (d, $J = 2.0$ Hz, 1H), 4.59-4.54 (m, 1H), 3.50-3.47 (m, 1H), 3.22 (s, 3H), 2.60-2.54 (m, 1H), 2.48-2.32 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ ppm: 196.6, 165.2, 148.7, 145.0, 140.9, 139.4, 137.2, 133.3, 132.5, 129.4, 129.3, 129.0, 128.6, 128.5, 128.3, 127.5, 127.0, 126.1, 109.8, 76.1, 52.1, 46.3, 41.5, 38.2; HRMS (ESI) Calcd. For $\text{C}_{31}\text{H}_{27}\text{NO}_3\text{SNa}^+$ $[\text{M}+\text{Na}]^+$ 516.1604, found 516.1613.

(*2S,3S,4R*)-3-(4-fluorophenyl)-*N*-methyl-2-(2-oxo-2-phenylethyl)-*N*,4-diphenyl-3,4-dihydro-2*H*-pyran-6-carboxamide **3am**:




White solid, M.p.: 128-129 °C; yield: 90%; $[\alpha]^{25}_D = +71$ (*c* 0.1, CH₂Cl₂); HPLC (Chiralpak IA, *i*-propanol/hexane = 30/70, flow rate 1.0 mL/min, λ = 254 nm), t_1 = 13.41 min (major), t_2 = 20.31 min (minor), *ee* = 90%; ¹H NMR (400 MHz, CDCl₃) δ ppm: 7.62-7.60 (m, 2H), 7.52-7.44 (m, 1H), 7.35-7.31 (m, 2H), 7.20-7.14 (m, 3H), 7.07-7.05 (m, 2H), 7.02-6.99 (m, 3H), 6.75-6.71 (m, 4H), 6.61-6.58 (m, 2H), 5.47 (d, *J* = 2.1 Hz, 1H), 4.56-4.51 (m, 1H), 3.47-3.44 (m, 1H), 3.24 (s, 3H), 2.59-2.53 (m, 1H), 2.51-2.45 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ ppm: 196.4, 165.0, 161.8 (*J* = 244.3 Hz), 148.2, 144.8, 141.8, 139.6, 135.3, 135.2, 133.1, 129.8, 129.1, 128.4, 128.2 (*J* = 8.9 Hz), 127.8, 126.8, 126.7, 126.2, 125.9, 115.5 (*J* = 21.2 Hz), 110.3, 75.8, 51.3, 46.9, 41.3, 38.0; HRMS (ESI) Calcd. For C₃₃H₂₈FNO₃Na⁺ [M+Na]⁺ 528.1945, found 528.1953.

(*2S,3S,4R*)-3-(4-chlorophenyl)-*N*-methyl-2-(2-oxo-2-phenylethyl)-*N*,4-diphenyl-3,4-dihydro-2*H*-pyran-6-carboxamide **3an**:




White solid, M.p.: 161-162 °C; yield: 87%; $[\alpha]^{25}_D = +90$ (*c* 0.1, CH₂Cl₂); HPLC (Chiralpak IA, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm), t_1 = 18.61 min (major), t_2 = 27.62 min (minor), *ee* = 90%; ¹H NMR (400 MHz, CDCl₃) δ ppm: 7.62-7.60 (m, 2H), 7.48-7.44 (m, 1H), 7.35-7.31 (m, 2H), 7.18-7.15 (m, 3H), 7.07-7.00 (m, 7H), 6.70-6.68 (m, 2H), 6.61-6.59 (m, 2H), 5.47 (d, *J* = 2.2 Hz, 1H), 4.56-4.50 (m, 1H), 3.47-3.44 (m, 1H), 3.24 (s, 3H), 2.59-2.52 (m, 1H), 2.49-2.44 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ ppm: 196.3, 165.0, 148.2, 144.8, 141.7, 138.1, 136.9, 133.1, 132.9, 129.7, 129.1, 128.8, 128.4, 128.2, 128.1, 127.7, 126.8, 125.9, 110.2, 75.7, 51.4, 46.8, 41.2, 38.0; HRMS (ESI) Calcd. For C₃₃H₂₈ClNO₃Na⁺ [M+Na]⁺ 544.1650, found 544.1652.

(*2S,3S,4R*)-3-(4-bromophenyl)-*N*-methyl-2-(2-oxo-2-phenylethyl)-*N*,4-diphenyl-3,4-dihydro-2*H*-pyran-6-carboxamide **3ao**:




White solid, M.p.: 175-176 °C; yield: 92%; $[\alpha]^{25}_D = +123$ (*c* 0.1, CH₂Cl₂); HPLC (Chiraldak IA, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm), t_1 = 15.80 min (major), t_2 = 23.15 min (minor), *ee* = 90%; ¹H NMR (400 MHz, CDCl₃) δ ppm: 7.62-7.60 (m, 2H), 7.48-7.44 (m, 1H), 7.35-7.32 (m, 2H), 7.18-7.14 (m, 5H), 7.07-7.01 (m, 5H), 6.64-6.59 (m, 4H), 5.46 (d, *J* = 2.2 Hz, 1H), 4.55-4.50 (m, 1H), 3.47-3.44 (m, 1H), 3.24 (s, 3H), 2.59-2.51 (m, 1H), 2.49-2.44 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ ppm: 196.3, 165.0, 148.2, 144.8, 141.7, 138.6, 136.9, 133.1, 131.7, 130.0, 129.1, 128.4, 128.3, 128.1, 127.7, 126.8, 125.9, 121.1, 110.2, 75.6, 51.5, 46.7, 41.2, 38.0; HRMS (ESI) Calcd. For C₃₃H₂₈BrNO₃Na⁺ [M+Na]⁺ 588.1145, found 588.1156.

(2*S*,3*S*,4*R*)-*N*-methyl-2-(2-oxo-2-phenylethyl)-*N*,4-diphenyl-3-(*p*-tolyl)-3,4-dihydro-2*H*-pyran-6-carboxamide 3ap:




White solid, M.p.: 123-124 °C; yield: 89%; $[\alpha]^{25}_D = +49$ (*c* 0.1, CH₂Cl₂); HPLC (Chiraldak IA, *i*-propanol/hexane = 40/60, flow rate 1.0 mL/min, λ = 254 nm), t_1 = 11.16 min (major), t_2 = 14.89 min (minor), *ee* = 90%; ¹H NMR (400 MHz, CDCl₃) δ ppm: 7.69-7.67 (m, 2H), 7.54-7.50 (m, 1H), 7.41-7.37 (m, 2H), 7.26-7.20 (m, 3H), 7.15-7.13 (m, 2H), 7.09-7.07 (m, 3H), 6.97-6.85 (m, 2H), 6.72-6.70 (m, 4H), 5.55 (d, *J* = 2.2 Hz, 1H), 4.65-4.60 (m, 1H), 3.59-3.56 (m, 1H), 3.31 (s, 3H), 2.65-2.59 (m, 1H), 2.56-2.47 (m, 2H), 2.19 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ ppm: 196.7, 165.3, 148.5, 142.6, 142.4, 139.9, 137.3, 136.7, 133.2, 129.9, 128.8, 128.6, 128.3, 128.3, 128.1, 127.3, 126.8, 125.9, 110.4, 76.0, 52.2, 47.0, 41.7, 38.3, 21.3; HRMS (ESI) Calcd. For C₃₄H₃₁NO₃Na⁺ [M+Na]⁺ 524.2196, found 524.2208.

(2*S*,3*S*,4*R*)-3-(4-methoxyphenyl)-*N*-methyl-2-(2-oxo-2-phenylethyl)-*N*,4-diphenyl-3,4-dihydro-2*H*-pyran-6-carboxamide 3aq:




White solid, M.p.: 144-145 °C; yield: 90%; $[\alpha]^{25}_D = +107$ (*c* 0.1, CH₂Cl₂); HPLC (Chiralpak IA, *i*-propanol/hexane = 40/60, flow rate 1.0 mL/min, λ = 254 nm), t_1 = 10.30 min (major), t_2 = 18.51 min (minor), *ee* = 92%; ¹H NMR (400 MHz, CDCl₃) δ ppm: 7.72-7.68 (m, 2H), 7.56-7.53 (m, 1H), 7.44-7.40 (m, 2H), 7.30-7.21 (m, 3H), 7.19-7.09 (m, 5H), 6.87-6.85 (m, 2H), 6.65-6.61 (m, 4H), 5.56 (d, *J* = 2.2 Hz, 1H), 4.69-4.64 (m, 1H), 3.73 (s, 3H), 3.59-3.56 (m, 1H), 3.34 (s, 3H), 2.70-2.64 (m, 1H), 2.57-2.51 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ ppm: 196.6, 165.2, 158.2, 148.1, 144.9, 139.7, 137.1, 134.2, 133.0, 129.1, 128.7, 128.6, 128.3, 128.1, 127.1, 126.7, 125.9, 113.4, 110.7, 75.9, 55.1, 52.1, 45.9, 41.4, 38.0; HRMS (ESI) Calcd. For C₃₄H₃₁NO₄Na⁺ [M+Na]⁺ 540.2145, found 540.2153.

(2*S*,3*S*,4*R*)-3-(4-ethylphenyl)-*N*-methyl-2-(2-oxo-2-phenylethyl)-*N*,4-diphenyl-3,4-dihydro-2*H*-pyran-6-carboxamide **3ar**:



White solid, M.p.: 146-147 °C; yield: 90%; $[\alpha]^{25}_D = +152$ (*c* 0.1, CH₂Cl₂); HPLC (Chiralpak IA, *i*-propanol/hexane = 40/60, flow rate 1.0 mL/min, λ = 254 nm), t_1 = 11.15 min (major), t_2 = 15.43 min (minor), *ee* = 92%; ¹H NMR (400 MHz, CDCl₃) δ ppm: 7.69-7.67 (m, 2H), 7.54-7.49 (m, 1H), 7.41-7.37 (m, 2H), 7.25-7.20 (m, 3H), 7.15-7.13 (m, 2H), 7.08-7.06 (m, 3H), 6.99-6.92 (m, 2H), 6.75-6.69 (m, 4H), 5.56 (d, *J* = 2.2 Hz, 1H), 4.66-4.61 (m, 1H), 3.60-3.57 (m, 1H), 3.31 (s, 3H), 2.65-2.46 (m, 5H), 1.11 (t, *J* = 7.6 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ ppm: 196.6, 165.2, 148.2, 144.9, 143.0, 142.3, 137.1, 136.6, 132.9, 129.1, 128.3, 128.2, 128.1, 128.1, 127.8, 126.7, 126.5, 125.9, 110.5, 76.1, 51.6, 46.6, 41.5, 38.0, 28.3, 15.3; HRMS (ESI) Calcd. For C₃₅H₃₃NO₃Na⁺ [M+Na]⁺ 538.2353, found 538.2351.


(2*S*,3*S*,4*R*)-2-((*Z*)-2-(hydroxyimino)-2-phenylethyl)-*N*-methyl-*N*,3,4-triphenyl-3,4-dihydro-2*H*-pyran-6-carboxamide **4**:



White solid, M.p.: 157-158 °C; yield: 87%; $[\alpha]^{25}_D = +86$ (*c* 0.1, CH₂Cl₂); HPLC (Chiralpak IA, *i*-propanol/hexane = 40/60, flow rate 1.0 mL/min, λ = 254 nm), t_1 = 10.91 min (major), t_2 = 13.46 min (minor), *ee* = 95%; ¹H NMR (400 MHz, CDCl₃) δ ppm: 7.48-7.46 (m, 2H), 7.39-7.36 (m, 3H), 7.27-7.23 (m, 4H), 7.15-7.14 (m, 3H), 7.07-6.99 (m, 5H), 6.82-6.81 (m, 2H), 6.62-6.61 (m, 2H), 5.34 (s, 1H), 4.43-4.32 (m, 1H), 3.58-3.42 (m, 1H), 3.27 (s, 3H), 2.70-2.61 (m, 2H), 2.47-2.42 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ ppm: 165.7, 156.4, 148.6, 144.2, 142.1, 139.8, 136.3, 129.1, 129.0, 128.4,


128.2, 128.0, 127.8, 127.1, 127.0, 126.8, 126.5, 125.9, 109.5, 77.0, 53.4, 46.9, 37.7, 31.4; HRMS (ESI) Calcd. For $C_{33}H_{30}N_2O_3Na^+$ $[M+Na]^+$ 525.2149, found 525.2151.

(*2S,3S,4R*)-2-(2-hydroxy-2-phenylethyl)-*N*-methyl-*N*,3,4-triphenyl-3,4-dihydro-2*H*-pyran-6-carboxamide **5**:




White solid, M.p.: 121-122 °C; yield: 42%; $[\alpha]^{25}_D = +78$ (*c* 0.1, CH₂Cl₂); HPLC (Chiralpak IA, *i*-propanol/hexane = 40/60, flow rate 1.0 mL/min, λ = 254 nm), t_1 = 10.92 min (major), t_2 = 13.88 min (minor), *ee* = 95%; ¹H NMR (400 MHz, CDCl₃) δ ppm: 7.39-7.35 (m, 2H), 7.30-7.22 (m, 3H), 7.18-7.14 (m, 2H), 7.11-7.93 (m, 9H), 6.66-6.64 (m, 2H), 6.50-6.48 (m, 2H), 5.49 (d, *J* = 1.7 Hz, 1H), 4.48 (d, *J* = 9.1 Hz, 1H), 4.18-4.13 (m, 1H), 3.47-3.43 (m, 1H), 3.34 (s, 3H), 2.46-2.30 (m, 2H), 1.38-1.23 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ ppm: 165.6, 148.0, 145.3, 144.8, 142.1, 139.8, 129.5, 128.5, 128.2, 128.0, 127.8, 127.0, 126.9, 126.6, 126.5, 125.8, 125.5, 111.7, 77.1, 69.2, 52.6, 47.2, 42.0, 38.2; HRMS (ESI) Calcd. For $C_{33}H_{31}NO_3Na^+$ $[M+Na]^+$ 512.2196, found 512.2208.

(*2S,3S,4R*)-2-(2-hydroxy-2-phenylethyl)-*N*-methyl-*N*,3,4-triphenyl-3,4-dihydro-2*H*-pyran-6-carboxamide **5'**:



White solid, M.p.: 133-134 °C; yield: 43%; $[\alpha]^{25}_D = +18$ (*c* 0.1, CH₂Cl₂); HPLC (Chiralpak IA, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, λ = 254 nm), t_1 = 15.51 min (major), t_2 = 20.02 min (minor), *ee* = 94%; ¹H NMR (400 MHz, CDCl₃) δ ppm: 7.47-7.43 (m, 2H), 7.36-7.30 (m, 3H), 7.26-7.22 (m, 2H), 7.19-7.00 (m, 9H), 6.74-6.72 (m, 2H), 6.63-6.56 (m, 2H), 5.55 (d, *J* = 1.7 Hz, 1H), 4.57 (d, *J* = 9.1 Hz, 1H), 4.25-4.20 (m, 1H), 3.54-3.51 (m, 1H), 3.41 (s, 3H), 2.55-2.40 (m, 2H), 1.46-1.31 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ ppm: 165.5, 148.0, 145.3, 144.8, 142.1, 139.8, 129.5, 128.5, 128.2, 128.0, 127.8, 127.0, 126.9, 126.6, 126.5, 125.8, 125.5, 111.7, 77.1, 69.2, 52.6, 47.2, 42.0, 38.2; HRMS (ESI) Calcd. For $C_{33}H_{31}NO_3Na^+$ $[M+Na]^+$ 512.2196, found 512.2208.

(*4'S,5'S,6'S*)-1-methyl-6'-(2-oxo-2-phenylethyl)-4',5'-diphenyl-3',4',5',6'-tetrahydrospiro[indoline-3,2'-pyran]-2-one **6**:



6

White solid, M.p.: 175-176 °C; yield: 89%; $[\alpha]^{25}_D = +83$ (*c* 0.1, CH₂Cl₂); HPLC (Chiralpak IA, *i*-propanol/hexane = 30/70, flow rate 1.0 mL/min, λ = 254 nm), t_1 = 8.29 min (major), t_2 = 13.53 min (minor), *ee* = 95%; ¹H NMR (400 MHz, CDCl₃) δ ppm: 8.13-8.11 (m, 1H), 7.77-7.64 (m, 2H), 7.42-7.35 (m, 2H), 7.30-7.21 (m, 3H), 7.15-7.00 (m, 10H), 6.83-6.82 (m, 1H), 5.34-5.29 (m, 1H), 3.76-3.69 (m, 1H), 3.44-3.78 (m, 1H), 3.22-3.17 (m, 1H), 3.09 (s, 1H), 2.69-2.59 (m, 2H), 1.88-1.84 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ ppm: 197.5, 174.8, 143.5, 142.5, 139.6, 137.2, 132.8, 129.9, 129.7, 128.6, 128.3, 128.3, 128.1, 127.7, 127.0, 126.5, 125.6, 122.7, 109.1, 77.9, 73.5, 53.7, 44.0, 43.0, 39.0, 26.4.

5. Crystallographic data collection for compound 3ba.









Table 1 Crystal data and structure refinement for 202010220.

Identification code	202010220
Empirical formula	C ₃₃ H ₂₈ FNO ₃
Formula weight	505.56
Temperature/K	293(2)
Crystal system	monoclinic
Space group	P2 ₁
a/Å	9.5394(8)
b/Å	11.1681(9)
c/Å	12.3498(12)
α/	90
β/	101.756(10)
γ/	90
Volume/Å ³	1288.1(2)
Z	2
ρ _{calc} g/cm ³	1.303
μ/mm ⁻¹	0.709
F(000)	532.0
Crystal size/mm ³	0.2 × 0.13 × 0.1
Radiation	CuKα ($\lambda = 1.54184$)
2Θ range for data collection/	7.312 to 143.35
Index ranges	-11 ≤ h ≤ 11, -13 ≤ k ≤ 13, -15 ≤ l ≤ 14
Reflections collected	10480
Independent reflections	4794 [$R_{\text{int}} = 0.0277$, $R_{\text{sigma}} = 0.0386$]
Data/restraints/parameters	4794/1/344
Goodness-of-fit on F ²	1.080
Final R indexes [I>=2σ (I)]	$R_1 = 0.0396$, $wR_2 = 0.0911$
Final R indexes [all data]	$R_1 = 0.0468$, $wR_2 = 0.0978$
Largest diff. peak/hole / e Å ⁻³	0.11/-0.18



Flack parameter -0.02(13)

6. HPLC chromatograms of compounds.







3ba





3ba







3ca





3ca







3da





3da







3ea





3ea






3fa


wmc10000.che





3fa

wmc10021.che







3ga





3ga







3ha





3ha







3ia





3ia




Calculation Result TimeTable					
	Retention Time	Peak Area	Peak Height	Peak Area(%)	Peak Width
1	10.16	110072	4328	4.07%	0.96 BB
2	12.94	2594293	67812	95.93%	4.238 BB




3ja





3ja







3ka





3ka







3la





3la







3ma





3ma







3na





3na







3oa





3oa







3pa





3pa







3ab





3ab







3ac





3ac







3ad




3ad







3ae




Migration Result		Calculation Result		TimeTable		
No.	Retention Time	Peak Area	Peak Height	Peak Area(%)	Peak Width	Peak Type
1	11.11	2095945	105359	50.96%	1.76	BB
2	13.54	2017068	86703	49.04%	2.043	BB
		4,113,013	192,062	100.00%		





3ae




Migration Result		Calculation Result		TimeTable		
No.	Retention Time	Peak Area	Peak Height	Peak Area(%)	Peak Width	Peak Type
1	11.14	30086	1753	3.07%	0.861	BB
2	13.55	948477	40817	96.93%	1.653	BB
al		978,563	42,570	100.00%		




3af





3af







3ag





3ag







3ah





3ah







3ai





3ai







3aj





3aj







3ak





3ak







3al





3al




TimeResult Calculation Result TimeTable					
Retention Time	Peak Area	Peak Height	Peak Area(%)	Peak Width	Peak Type
1 5.44	5347366	412889	96.50%	1.66 BB	
2 13.38	193964	7210	3.50%	0.878 BB	




3am





3am







3an





3an







3ao





3ao







3ap





3ap







3aq





3aq







3ar





3ar







4





4







5





5







5'





5'






6






6




7. NMR Spectra of compounds.


¹H NMR spectrum of compound **3aa** (CDCl₃, 400 MHz)




¹H NMR spectrum of compound **3ba** (CDCl₃, 400 MHz)




¹³C NMR spectrum of compound **3ba** (CDCl₃, 100 MHz)




¹⁹F NMR spectrum of compound **3ba** (CDCl_3 , 376 MHz)




¹H NMR spectrum of compound **3ca** (CDCl_3 , 400 MHz)




¹³C NMR spectrum of compound **3ca** (CDCl_3 , 100 MHz)




¹H NMR spectrum of compound **3da** (CDCl_3 , 400 MHz)




¹³C NMR spectrum of compound **3da** (CDCl_3 , 100 MHz)




¹H NMR spectrum of compound **3ea** (CDCl_3 , 400 MHz)




¹³C NMR spectrum of compound **3ea** (CDCl_3 , 100 MHz)




¹H NMR spectrum of compound **3fa** (CDCl_3 , 400 MHz)




¹³C NMR spectrum of compound **3fa** (CDCl_3 , 100 MHz)




¹H NMR spectrum of compound **3ga** (CDCl₃, 400 MHz)




¹³C NMR spectrum of compound **3ga** (CDCl₃, 100 MHz)




¹H NMR spectrum of compound **3ha** (CDCl_3 , 400 MHz)




¹³C NMR spectrum of compound **3ha** (CDCl_3 , 100 MHz)




¹H NMR spectrum of compound **3ia** (CDCl_3 , 400 MHz)




¹³C NMR spectrum of compound **3ia** (CDCl_3 , 100 MHz)




¹H NMR spectrum of compound **3ja** (CDCl_3 , 400 MHz)




¹³C NMR spectrum of compound **3ja** (CDCl_3 , 100 MHz)




¹H NMR spectrum of compound **3ka** (CDCl₃, 400 MHz)




¹³C NMR spectrum of compound **3ka** (CDCl₃, 100 MHz)




¹⁹F NMR spectrum of compound **3ka** (CDCl_3 , 376 MHz)




¹H NMR spectrum of compound **3la** (CDCl₃, 400 MHz)




¹³C NMR spectrum of compound **3la** (CDCl₃, 100 MHz)




¹H NMR spectrum of compound **3ma** (CDCl_3 , 400 MHz)




¹³C NMR spectrum of compound **3ma** (CDCl_3 , 100 MHz)




¹H NMR spectrum of compound **3na** (CDCl_3 , 400 MHz)




¹³C NMR spectrum of compound **3na** (CDCl_3 , 100 MHz)




¹H NMR spectrum of compound **3oa** (CDCl_3 , 400 MHz)




¹³C NMR spectrum of compound **3oa** (CDCl_3 , 100 MHz)




¹H NMR spectrum of compound **3pa** (CDCl_3 , 400 MHz)




¹³C NMR spectrum of compound **3pa** (CDCl_3 , 100 MHz)




¹H NMR spectrum of compound **3ab** (CDCl₃, 400 MHz)




¹³C NMR spectrum of compound **3ab** (CDCl₃, 100 MHz)




¹⁹F NMR spectrum of compound **3ab** (CDCl_3 , 376 MHz)




¹H NMR spectrum of compound **3ac** (CDCl_3 , 400 MHz)




¹³C NMR spectrum of compound **3ac** (CDCl_3 , 100 MHz)




¹H NMR spectrum of compound **3ad** (CDCl₃, 400 MHz)




¹³C NMR spectrum of compound **3ad** (CDCl₃, 100 MHz)




¹H NMR spectrum of compound **3ae** (CDCl_3 , 400 MHz)




¹³C NMR spectrum of compound **3ae** (CDCl_3 , 100 MHz)




¹H NMR spectrum of compound **3af** (CDCl_3 , 400 MHz)




¹³C NMR spectrum of compound **3af** (CDCl_3 , 100 MHz)




¹H NMR spectrum of compound **3ag** (CDCl₃, 400 MHz)




¹³C NMR spectrum of compound **3ag** (CDCl₃, 100 MHz)




¹H NMR spectrum of compound **3ah** (CDCl_3 , 400 MHz)




¹³C NMR spectrum of compound **3ah** (CDCl_3 , 100 MHz)




¹H NMR spectrum of compound **3ai** (CDCl_3 , 400 MHz)




¹³C NMR spectrum of compound **3ai** (CDCl_3 , 100 MHz)




¹H NMR spectrum of compound **3aj** (CDCl₃, 400 MHz)




¹³C NMR spectrum of compound **3aj** (CDCl₃, 100 MHz)




¹H NMR spectrum of compound **3ak** (CDCl_3 , 400 MHz)




¹³C NMR spectrum of compound **3ak** (CDCl_3 , 100 MHz)




¹H NMR spectrum of compound **3al** (CDCl_3 , 400 MHz)




¹³C NMR spectrum of compound **3al** (CDCl_3 , 100 MHz)




¹H NMR spectrum of compound **3am** (CDCl₃, 400 MHz)




¹³C NMR spectrum of compound **3am** (CDCl₃, 100 MHz)




¹⁹F NMR spectrum of compound **3am** (CDCl₃, 376 MHz)




¹H NMR spectrum of compound **3an** (CDCl_3 , 400 MHz)




¹³C NMR spectrum of compound **3an** (CDCl_3 , 100 MHz)




¹H NMR spectrum of compound **3ao** (CDCl_3 , 400 MHz)




¹³C NMR spectrum of compound **3ao** (CDCl_3 , 100 MHz)




¹H NMR spectrum of compound **3ap** (CDCl₃, 400 MHz)




¹³C NMR spectrum of compound **3ap** (CDCl₃, 100 MHz)




¹H NMR spectrum of compound **3aq** (CDCl_3 , 400 MHz)




¹³C NMR spectrum of compound **3aq** (CDCl_3 , 100 MHz)




¹H NMR spectrum of compound **3ar** (CDCl_3 , 400 MHz)




¹³C NMR spectrum of compound **3ar** (CDCl_3 , 100 MHz)




¹H NMR spectrum of compound 4 (CDCl₃, 400 MHz)




¹³C NMR spectrum of compound 4 (CDCl₃, 100 MHz)




¹H NMR spectrum of compound **5** (CDCl₃, 400 MHz)




¹³C NMR spectrum of compound **5** (CDCl₃, 100 MHz)




¹H NMR spectrum of compound **5'** (CDCl₃, 400 MHz)




¹³C NMR spectrum of compound **5'** (CDCl₃, 100 MHz)




¹H NMR spectrum of compound **6** (CDCl₃, 400 MHz)



¹³C NMR spectrum of compound **6** (CDCl₃, 100 MHz)



¹³C dept-135 NMR spectrum of compound **6** (CDCl₃, 100 MHz)



8. References

- [1] X. Li, X. Kong, S. Yang, M. Meng, X. Zhan, M. Zeng, X. Fang, *Org. Lett.* **2019**, *21*, 1979–1983.
- [2] X.-C. Yang, M.-M. Liu, F. Mathey, H. Yang, Y.-Z. Hua, M.-C. Wang, *J. Org. Chem.* **2019**, *84*, 7762–7775.